UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Randomized Phase II Study of Dulanermin in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Advanced Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2011-11, Vol.29 (33), p.4442-4451

2011

Volltextzugriff (PDF)

Survival by histologic subtype in stage IV nonsmall cell lung cancer based on data from the Surveillance, Epidemiology and End Results Program

Clinical epidemiology, 2011, Vol.3 (Issue 1), p.139-148

2011

Volltextzugriff (PDF)

TRAIL Receptor Agonist Conatumumab With Modified FOLFOX6 Plus Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer: A Randomized Phase 1b/2 Trial

Cancer, 2013-12, Vol.119 (24), p.4290-4298

2013

Volltextzugriff (PDF)

Natural History of Rising Serum Prostate-Specific Antigen in Men With Castrate Nonmetastatic Prostate Cancer

Journal of clinical oncology, 2005-05, Vol.23 (13), p.2918-2925

2005

Volltextzugriff (PDF)

Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study

The lancet oncology, 2011-04, Vol.12 (4), p.369-376

2011

Volltextzugriff (PDF)

Challenges in developing a validated biomarker for angiogenesis inhibitors: the motesanib experience

PloS one, 2014-10, Vol.9 (10), p.e108048

2014

Volltextzugriff (PDF)

Osteonecrosis of the Jaw and Bisphosphonates

The New England journal of medicine, 2005-07, Vol.353 (1), p.99-102

2005

Volltextzugriff (PDF)

International, Randomized, Placebo-Controlled, Double-Blind Phase III Study of Motesanib Plus Carboplatin/Paclitaxel in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer: MONET1

Journal of clinical oncology, 2012-08, Vol.30 (23), p.2829-2836

2012

Volltextzugriff (PDF)

TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first‐line treatment of metastatic colorectal cancer

Cancer, 2013-12, Vol.119 (24), p.4290-4298

2013

Volltextzugriff (PDF)

Renal Failure with the Use of Zoledronic Acid

The New England journal of medicine, 2003-10, Vol.349 (17), p.1676-1679

2003

Volltextzugriff (PDF)

Predictive Value of Bone Resorption and Formation Markers in Cancer Patients With Bone Metastases Receiving the Bisphosphonate Zoledronic Acid

Journal of clinical oncology, 2005-08, Vol.23 (22), p.4925-4935

2005

Volltextzugriff (PDF)

Bone Turnover Markers as Predictors of Skeletal Complications in Prostate Cancer, Lung Cancer, and Other Solid Tumors

JNCI : Journal of the National Cancer Institute, 2005-01, Vol.97 (1), p.59-69

2005

Volltextzugriff (PDF)

Tumor MET Expression and Gene Amplification in Chinese Patients with Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer

Molecular cancer therapeutics, 2015-11, Vol.14 (11), p.2634-2641

2015

Volltextzugriff (PDF)

Biomarkers as Predictors of Response to Treatment with Motesanib in Patients with Progressive Advanced Thyroid Cancer

The journal of clinical endocrinology and metabolism, 2010-11, Vol.95 (11), p.5018-5027

2010

Volltextzugriff (PDF)

First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: A Phase I/II open-label and double-blind study

European journal of cancer (1990), 2012-03, Vol.48 (4), p.547-563

2012

Volltextzugriff (PDF)

A Randomized Phase 2 Study of Paclitaxel and Carboplatin with or without Conatumumab for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

Journal of thoracic oncology, 2013-03, Vol.8 (3), p.329-337

2013

Volltextzugriff (PDF)

Markers of Bone Metabolism and Survival in Men with Hormone-Refractory Metastatic Prostate Cancer

Clinical cancer research, 2006-06, Vol.12 (11), p.3361-3367

2006

Volltextzugriff (PDF)

Motesanib Plus Carboplatin/Paclitaxel in Patients With Advanced Squamous Non–Small-Cell Lung Cancer: Results From the Randomized Controlled MONET1 Study

Journal of thoracic oncology, 2014-08, Vol.9 (8), p.1154-1161

2014

Volltextzugriff (PDF)

Predictors of Skeletal Complications in Men with Hormone-Refractory Metastatic Prostate Cancer

Urology (Ridgewood, N.J.), 2007-08, Vol.70 (2), p.315-319

2007

Volltextzugriff (PDF)

Inhibition of disease progression by a novel retinoid antagonist in animal models of arthritis

Journal of rheumatology, 2003-02, Vol.30 (2), p.355

2003

Volltextzugriff (PDF)

The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors

BMC cancer, 2013-05, Vol.13 (1), p.242-242, Article 242

2013

Volltextzugriff (PDF)

Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications

Clinical lung cancer, 2004-11, Vol.6 (3), p.170-174

2004

Volltextzugriff (PDF)

An open-label, multicenter, phase Ib/II study of the ATR inhibitor SC0245 in combination with irinotecan in patients with relapsed and refractory extensive stage small cell lung cancer (ES-SCLC)

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.8102-8102

2024

Volltextzugriff (PDF)

An open-label, single-arm, dose escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of the ATR inhibitor SC0245 in advanced solid malignancies

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.e15126-e15126

2024

Volltextzugriff (PDF)

IV Bisphosphonate therapy: making the case for calcium and vitamin D supplementation

Medical hypotheses, 2005, Vol.64 (4), p.879-880

2005

Volltextzugriff (PDF)

1 – 25 von 84

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(73)
Mit Volltextzugriff
(72)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Randomized Phase II Study of Dulanermin in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Advanced Non–Small-Cell Lung Cancer

Survival by histologic subtype in stage IV nonsmall cell lung cancer based on data from the Surveillance, Epidemiology and End Results Program

TRAIL Receptor Agonist Conatumumab With Modified FOLFOX6 Plus Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer: A Randomized Phase 1b/2 Trial

Natural History of Rising Serum Prostate-Specific Antigen in Men With Castrate Nonmetastatic Prostate Cancer

Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study

Challenges in developing a validated biomarker for angiogenesis inhibitors: the motesanib experience

Osteonecrosis of the Jaw and Bisphosphonates

International, Randomized, Placebo-Controlled, Double-Blind Phase III Study of Motesanib Plus Carboplatin/Paclitaxel in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer: MONET1

TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first‐line treatment of metastatic colorectal cancer

Renal Failure with the Use of Zoledronic Acid

Predictive Value of Bone Resorption and Formation Markers in Cancer Patients With Bone Metastases Receiving the Bisphosphonate Zoledronic Acid

Bone Turnover Markers as Predictors of Skeletal Complications in Prostate Cancer, Lung Cancer, and Other Solid Tumors

Tumor MET Expression and Gene Amplification in Chinese Patients with Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer

Biomarkers as Predictors of Response to Treatment with Motesanib in Patients with Progressive Advanced Thyroid Cancer

First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: A Phase I/II open-label and double-blind study

A Randomized Phase 2 Study of Paclitaxel and Carboplatin with or without Conatumumab for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

Markers of Bone Metabolism and Survival in Men with Hormone-Refractory Metastatic Prostate Cancer

Motesanib Plus Carboplatin/Paclitaxel in Patients With Advanced Squamous Non–Small-Cell Lung Cancer: Results From the Randomized Controlled MONET1 Study

Predictors of Skeletal Complications in Men with Hormone-Refractory Metastatic Prostate Cancer

Inhibition of disease progression by a novel retinoid antagonist in animal models of arthritis

The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors

Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications

An open-label, multicenter, phase Ib/II study of the ATR inhibitor SC0245 in combination with irinotecan in patients with relapsed and refractory extensive stage small cell lung cancer (ES-SCLC)

An open-label, single-arm, dose escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of the ATR inhibitor SC0245 in advanced solid malignancies

IV Bisphosphonate therapy: making the case for calcium and vitamin D supplementation

Suchergebnisse filtern